The company, which has offices in Beverly, Massachusetts and Warwick, U.K., designed its dialysis system to be compact but with the performance of traditional machines. In 2022, the FDA cleared the system to perform intermittent hemodialysis (IHD), sustained low-efficiency dialysis, and CRRT (CVVHD and SCUF) without needing bags. Recently, there was an additional FDA clearance for home hemodialysis, offering a high dialysate flow (500 ml/minute) system.
On top of an expanded commercial presence in the U.S., Quanta officials plan to use the cash influx to support additional innovation.
“Our commitment to delivering innovative solutions for acute care has never been stronger,” Quanta CEO Alejandro Galindo said in a news release. “This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position.”
Novo Holdings, Glenview Capital and b2venture led the latest funding round.
“Quanta’s compelling product-market fit within the $1.5 billion acute care segment is demonstrated by its ability to win contracts over well-established legacy CRRT and IHD competitors,” said Robert Ghenchev, managing partner of growth investments at Novo Holdings. “The recent FDA clearance for the home setting is transformational for patients and significantly expands Quanta’s addressable market into the chronic and sub-acute segments.”
